Ruben A. Mesa

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

Ross L. Levine, Martha Wadleigh, Jan Cools et al. · Cancer Cell · 2005 · 3K citations · Full text

Medicine, Genetics, Hematology +14

A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis

Srđan Verstovšek, Ruben A. Mesa, Jason Gotlib et al. · New England Journal of Medicine · 2012 · 2K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +12

Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study

Nicole M. Kuderer, Toni K. Choueiri, Dimpy P. Shah et al. · The Lancet · 2020 · 1.8K citations · Full text

Medicine, Clinical Sciences, Oncology +8

New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment

Francisco Cervantes, Brigitte Dupriez, Arturo Pereira et al. · Blood · 2008 · 1.2K citations · Full text

Medicine, Hematology, Pathology +16

Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis

Srđan Verstovšek, Hagop M. Kantarjian, Ruben A. Mesa et al. · New England Journal of Medicine · 2010 · 1.2K citations · Full text

Medicine, Hematology, Pharmacology +13